Alpha Cognition Inc (ACOG)

Alpha Cognition's stock has been influenced by several events over the past six months. The company announced an upsized public offering and Nasdaq listing in November 2024, providing capital for commercialization and development. It voluntarily delisted from the CSE in December 2024. Patent approvals were received for ALPHA-1062 and ZUNVEYL. Financial results included Q3 2025 revenue of $2.8 million with increased pharmacy orders, and full-year 2025 revenue of $10.2 million. Bethany Sensenig was appointed to the Board of Directors in April 2026. Analyst coverage included a "buy" recommendation from Craig-Hallum, but a downgrade to "sell" from Wall Street Zen. The stock's price has decreased by 6.89% over the last 12 months.

Based on the available information, there is no explicit mention or indication of demand seasonality for Alpha Cognition, Inc.'s products and services. The company's focus is on the commercialization and adoption of ZUNVEYL in the long-term care market for Alzheimer's disease, with reported quarter-over-quarter growth in pharmacy orders and an expanding prescriber base. This suggests a steady, growing demand rather than seasonal fluctuations.

Alpha Cognition, Inc. (ACOG) is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's and ALS, operating in the Biotechnology industry. Its key products include ZUNVEYL (benzgalantamine), an FDA-approved oral tablet for mild-to-moderate Alzheimer's, designed with minimal gastrointestinal side effects and unique binding properties. ALPHA-1062 is being developed in sublingual and intranasal formulations for cognitive impairment related to mild traumatic brain injury. Additionally, ALPHA-0602, ALPHA-0702, and ALPHA-0802 are preclinical programs targeting neurodegenerative diseases.

Alpha Cognition, Inc. develops treatments for neurodegenerative diseases in the United States and Canada. The company also has a licensing agreement for ZUNVEYL in China, indicating potential expansion into the Asian market.

Alpha Cognition's brand reputation has been generally positive, driven by progress in developing treatments for neurodegenerative diseases. The FDA approval of ZUNVEYL is a significant positive. Positive clinical and preclinical data announcements contribute to a reputation of scientific advancement. Securing new U.S. patents strengthens the company's intellectual property. The consensus "Buy" rating from analysts suggests a generally favorable view.

Alpha Cognition Inc. has a significant institutional ownership presence, with 27 institutional owners and shareholders holding 9,894,648 shares. Major institutional shareholders include Opaleye Management Inc., Solas Capital Management, LLC, and AWM Investment Company, Inc. The ownership breakdown includes private companies (1.02%), individual insiders (9.53%), institutions (14.5%), and the general public (36.2%).